Celldex Therapeutics – Metastatic gpNMB Expressing Triple Negative Breast Cancer

Access Program Information

Celldex endeavors to make investigational products available to patients with
life-threatening diseases who have exhausted other treatment options and where there is a
reasonable expectation of benefit over risk. Requests for expanded access to glembatumumab
vedotin in patients with gpNMB expressing triple negative breast cancer will be considered.